BeiGene (HKSE:06160) Total Current Assets : HK$30,570 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BeiGene's total current assets for the quarter that ended in Mar. 2024 was HK$30,570 Mil.

BeiGene Total Current Assets Historical Data

The historical data trend for BeiGene's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Current Assets Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

9,152.31

38,454.77

59,380.65

40,539.19

32,827.82

BeiGene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															36,922.78	34,476.32	31,733.15	32,827.82	30,570.33

BeiGene Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BeiGene's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	24791.429	+	3091.79	+	3249.83	+	1694.774
	=	32,828

BeiGene's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	21852.534	+	3654.217	+	3499.58	+	1563.997
	=	30,570

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

BeiGene (HKSE:06160) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BeiGene's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	21852.534	-	18050.164	+	0.75 * 3405.305	+	0.5 * 3499.58
=	8,106

BeiGene Total Current Assets Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (HKSE:06160) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

BGNE:USA 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
Oyler John Victor	2101 Beneficial owner
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene (HKSE:06160) Headlines

No Headlines